Tags

Type your tag names separated by a space and hit enter

Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial.
J Glaucoma. 2006 Aug; 15(4):341-5.JG

Abstract

PURPOSE

To compare the additive effect of dorzolamide or carteolol to latanoprost on intraocular pressure (IOP) in glaucoma patients.

DESIGN

Prospective open-label randomized crossover clinical study.

METHODS

A total of 64 patients with primary open-angle glaucoma were treated with latanoprost 0.005% once daily for 3 months then randomized to receive latanoprost plus dorzolamide 1% 3 times daily (dorzolamide preceding group; n=32) or carteolol hydrochloride 2% twice daily (carteolol preceding group; n=32) for a further 3 months. Then, all patients were crossed over to the opposite treatment arm for a further 3 months. IOP was recorded each month at around the time same as on the baseline day.

RESULTS

Sixty-one patients (95%) completed this trial. In the dorzolamide preceding group, mean (+/-SD) IOP was 19.0+/-2.1 mm Hg at baseline and 16.0+/-2.1 mm Hg at the end of latanoprost monotherapy (P<0.01). Addition of dorzolamide reduced IOP to 15.0+/-1.3 mm Hg and this was not changed by switching to carteolol (15.1+/-1.7 mm Hg). In the carteolol preceding group, IOP was 19.1+/-1.9 mm Hg at baseline and 16.2+/-1.2 mm Hg at the end of latanoprost monotherapy (P<0.01). Addition of carteolol reduced IOP to 14.9+/-1.5 mm Hg, and after switching to dorzolamide IOP was 15.2+/-1.5 mm Hg. Mean additional IOP reduction was 0.9+/-1.2 mm Hg (5.6%) for the latanoprost-dorzolamide combination and 1.1+/-1.5 mm Hg (6.8%) for the latanoprost-carteolol combination. Hence, IOP reduction by carteolol and dorzolamide additionally to latanoprost was not different.

CONCLUSIONS

Both dorzolamide and carteolol reduce IOP additively when used in combination with latanoprost, and the additive effect of these drugs is equal.

Authors+Show Affiliations

Department of Ophthalmology, Tokyo Medical University, Hachioji Medical Center, Tokyo, Japan.No affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

16865013

Citation

Maruyama, Katsuhiko, and Shiroaki Shirato. "Additive Effect of Dorzolamide or Carteolol to Latanoprost in Primary Open-angle Glaucoma: a Prospective Randomized Crossover Trial." Journal of Glaucoma, vol. 15, no. 4, 2006, pp. 341-5.
Maruyama K, Shirato S. Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial. J Glaucoma. 2006;15(4):341-5.
Maruyama, K., & Shirato, S. (2006). Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial. Journal of Glaucoma, 15(4), 341-5.
Maruyama K, Shirato S. Additive Effect of Dorzolamide or Carteolol to Latanoprost in Primary Open-angle Glaucoma: a Prospective Randomized Crossover Trial. J Glaucoma. 2006;15(4):341-5. PubMed PMID: 16865013.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial. AU - Maruyama,Katsuhiko, AU - Shirato,Shiroaki, PY - 2006/7/26/pubmed PY - 2006/9/15/medline PY - 2006/7/26/entrez SP - 341 EP - 5 JF - Journal of glaucoma JO - J Glaucoma VL - 15 IS - 4 N2 - PURPOSE: To compare the additive effect of dorzolamide or carteolol to latanoprost on intraocular pressure (IOP) in glaucoma patients. DESIGN: Prospective open-label randomized crossover clinical study. METHODS: A total of 64 patients with primary open-angle glaucoma were treated with latanoprost 0.005% once daily for 3 months then randomized to receive latanoprost plus dorzolamide 1% 3 times daily (dorzolamide preceding group; n=32) or carteolol hydrochloride 2% twice daily (carteolol preceding group; n=32) for a further 3 months. Then, all patients were crossed over to the opposite treatment arm for a further 3 months. IOP was recorded each month at around the time same as on the baseline day. RESULTS: Sixty-one patients (95%) completed this trial. In the dorzolamide preceding group, mean (+/-SD) IOP was 19.0+/-2.1 mm Hg at baseline and 16.0+/-2.1 mm Hg at the end of latanoprost monotherapy (P<0.01). Addition of dorzolamide reduced IOP to 15.0+/-1.3 mm Hg and this was not changed by switching to carteolol (15.1+/-1.7 mm Hg). In the carteolol preceding group, IOP was 19.1+/-1.9 mm Hg at baseline and 16.2+/-1.2 mm Hg at the end of latanoprost monotherapy (P<0.01). Addition of carteolol reduced IOP to 14.9+/-1.5 mm Hg, and after switching to dorzolamide IOP was 15.2+/-1.5 mm Hg. Mean additional IOP reduction was 0.9+/-1.2 mm Hg (5.6%) for the latanoprost-dorzolamide combination and 1.1+/-1.5 mm Hg (6.8%) for the latanoprost-carteolol combination. Hence, IOP reduction by carteolol and dorzolamide additionally to latanoprost was not different. CONCLUSIONS: Both dorzolamide and carteolol reduce IOP additively when used in combination with latanoprost, and the additive effect of these drugs is equal. SN - 1057-0829 UR - https://www.unboundmedicine.com/medline/citation/16865013/Additive_effect_of_dorzolamide_or_carteolol_to_latanoprost_in_primary_open_angle_glaucoma:_a_prospective_randomized_crossover_trial_ L2 - https://doi.org/10.1097/01.ijg.0000212240.11219.49 DB - PRIME DP - Unbound Medicine ER -